MYMETICS - International Biotechnology Company

Mymetics is an international biotechnology company successfully focused on developing innovative vaccines interfering with early pathogen transmission events. We are currently focusing on HIV/AIDS and malaria vaccines.

Latest Press Release

Mymetics Corporation Acquires Preventive Malaria Vaccine From Pevion Biotech AG (Switzerland).

Successful Phase I and II Clinical Trials In Switzerland and the UK.
Results praised by an eminent member of the Pasteur Institute and of the malaria board of the Bill and Melinda Gates Foundation.

Nyon, Switzerland (May 19, 2008)
Mymetics Corporation (OTCBB: MYMX), a vaccine development company, made the acquisition of a preventive malaria vaccine from Pevion Biotech AG, a privately-held biotech company based in Switzerland. [more]

What makes Mymetics so innovative and promising?

Our successful pre-clinical trials and clinical results on HIV/AIDS and malaria vaccines.

Our original design - Prophylactics that combine innovative antigen engineering, minimal human protein homologies, and virosome technology.

Our pioneering approach - Vaccines that elicit protection for preventing early transmission events taking place within the first hours following exposure, such as the mucosal entry of pathogens. As a second line of defense, our vaccines elicit protection against later events as well.

Our "Best of Class" Network" –Support of reputable scientific partners and strategic alliances with both public and private institutions.